DexCom (NASDAQ:DXCM) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 6 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 5 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for DexCom, presenting an average target of $98.44, a high estimate of $120.00, and a low estimate of $85.00. Highlighting a 1.12% decrease, the current average has fallen from the previous average price target of $99.56.
Deciphering Analyst Ratings: An In-Depth Analysis
The perception of DexCom by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| William Plovanic | Canaccord Genuity | Raises | Buy | $99.00 | $89.00 |
| Lee Hambright | Bernstein | Raises | Outperform | $86.00 | $82.00 |
| Jayson Bedford | Raymond James | Lowers | Strong Buy | $99.00 | $115.00 |
| Shagun Singh | RBC Capital | Lowers | Outperform | $115.00 | $120.00 |
| Steven Lichtman | Oppenheimer | Lowers | Outperform | $105.00 | $115.00 |
| Robbie Marcus | JP Morgan | Raises | Neutral | $85.00 | $75.00 |
| Mike Kratky | Leerink Partners | Lowers | Outperform | $87.00 | $90.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $90.00 | $80.00 |
| Shagun Singh | RBC Capital | Lowers | Outperform | $120.00 | $130.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DexCom. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of DexCom's stock. This examination reveals shifts in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of DexCom's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on DexCom analyst ratings.
All You Need to Know About DexCom
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
A Deep Dive into DexCom's Financials
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: DexCom's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 1.97%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: DexCom's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 13.54%, the company may face hurdles in effective cost management.
Return on Equity (ROE): DexCom's ROE excels beyond industry benchmarks, reaching 6.1%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): DexCom's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 2.05%, the company may face hurdles in achieving optimal financial performance.
Debt Management: DexCom's debt-to-equity ratio stands notably higher than the industry average, reaching 1.31. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Understanding the Relevance of Analyst Ratings
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
